This Article Abstract Full Text (PDF) All Versions of this Article: 110/7/843    most recent 01.CIR.0000138848.58269.80v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwai, M. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Iwai, M. Articles by Horiuchi, M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors Animal models of human disease

(Circulation. 2004;110:843-848.)
© 2004 American Heart Association, Inc.

Original Articles

Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation

Masaru Iwai, MD, PhD^*; Hong-Wei Liu, MD^*; Rui Chen, MD; Ayumi Ide, BS; Shoko Okamoto, BS; Ryuji Hata, MD, PhD; Masahiro Sakanaka, MD, PhD; Tetsuya Shiuchi, MD, PhD; Masatsugu Horiuchi, MD, PhD

From the Departments of Medical Biochemistry (M.I., H.-W.L., R.C., A.I., S.O., T.S., M.H.) and Anatomy (R.H., M.S.), Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime, Japan.

Correspondence to Masatsugu Horiuchi, MD, PhD, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

Received September 9, 2003; de novo received January 27, 2004; revision received April 1, 2004; accepted April 4, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The role of angiotensin II receptor subtypes was investigated in focal brain ischemia induced by middle cerebral artery (MCA) occlusion.

Methods and Results— In Agtr2⁺ (wild-type) mice, MCA occlusion induced focal ischemia of 20% to 30% of the total area in coronal section of the brain. The ischemic area was significantly larger in angiotensin II type 2 receptor–deficient (Agtr2^–) mice than in Agtr2⁺ mice. The neurological deficit after MCA occlusion was also greater in Agtr2^– mice than in Agtr2⁺ mice. The decrease in surface cerebral blood flow after MCA occlusion was significantly exaggerated in the peripheral region of the MCA territory in Agtr2^– mice. Superoxide production and NADPH oxidase activity were enhanced in the ischemic area of the brain in Agtr2^– mice. An AT₁ receptor blocker, valsartan, at a nonhypotensive dose significantly inhibited the ischemic area, neurological deficit, and reduction of cerebral blood flow as well as superoxide production and NADPH oxidase activity in Agtr2⁺ mice. These inhibitory actions of valsartan were weaker in Agtr2^– mice.

Conclusions— These results suggest that AT₂ receptor stimulation has a protective effect on ischemic brain lesions, at least partly through the modulation of cerebral blood flow and superoxide production.

Key Words: stroke • angiotensin • ischemia • receptors • stress

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Angiotensin II (Ang II) is a potent vasoactive substance in the renin-angiotensin system (RAS), which has a variety of physiological actions, including vasoconstriction, aldosterone release, and cell growth.¹ Previous articles on the brain RAS studied primarily the regulatory mechanism of blood pressure.^2–5 Recent clinical studies, such as PROGRESS, SCOPE, and LIFE, indicated that blockade of RAS is important to prevent stroke.^6–8 Accumulating results of basic research also indicate the possible involvement of the central RAS in ischemic brain damage. Maeda et al⁹ reported that the core lesion area after middle cerebral artery (MCA) occlusion as well as mean arterial blood pressure was significantly reduced in angiotensinogen-knockout (AT₂KO) mice. Walter et al¹⁰ also reported that a smaller lesion area was observed after MCA occlusion in Ang II type 1 (AT₁) receptor–deficient mice. Moreover, Nishimura et al¹¹ reported that blockade of the AT₁ receptor by an AT₁ receptor blocker (ARB), candesartan, reduced the ischemic area after MCA occlusion in genetically hypertensive rats. These results suggest that AT₁ receptor stimulation is involved in the development of brain ischemic lesions and that blockade of the AT₁ receptor decreases ischemia at least partly through lowering of blood pressure. The major cardiovascular actions of Ang II have been reported to be mediated by the AT₁ receptor, whereas a second receptor subtype, known as the Ang II type 2 (AT₂) receptor, in brain ischemic lesions is still an enigma.

It has been reported that AT₂ receptor stimulation antagonizes the effects of AT₁ receptor stimulation in most tissues.^1,12–14 In the brain, AT₂ receptors are expressed not only in the vascular wall but also in the thalamus, hypothalamus, and specific brainstem nuclei.^15,16 When the AT₁ receptor is blocked by an ARB, unbound Ang II acts preferentially on the AT₂ receptor. These results point to the pathophysiological importance of the AT₂ receptor in the clinical use of ARBs, which are widely used in patients with hypertension and cardiovascular disease. We have previously reported that AT₂ receptor stimulation is involved in the beneficial effects of an ARB on vascular injury and cardiac remodeling.^17–19 However, the function of AT₂ receptor stimulation in the brain is not yet fully understood. Previous reports suggest that AT₂ receptor stimulation is involved in axonal regeneration²⁰ and in memory and behavior.^21–23 In the present study, we tried to clarify the roles of the AT₂ receptor in vascular remodeling, including blood flow in the penumbra and oxidative stress in ischemic brain damage after MCA occlusion.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Adult male AT₂ receptor–deficient mice (Agtr2^–; based on C57BL/6J strain bred in our laboratory) and wild-type mice (Agtr2⁺; age, 10 to 12 weeks; weight, 25 to 30 g) were used in this study. The mice were housed in a room in which lighting was controlled (12 hours on, 12 hours off) and room temperature was kept at 25°C. They were given a standard diet (MF, Oriental Yeast Co Ltd) and water ad libitum. The Animal Studies Committee of Ehime University approved the experimental protocol.

MCA Occlusion
Focal cerebral ischemia was induced by occlusion of the MCA by use of an intraluminal filament technique according to a method previously described.^9,24 Briefly, after a midline neck incision had been made, the left common and external carotid arteries were isolated and ligated. A nylon monofilament (Ethilon; Ethicon) coated with silicon resin (Xantopren; Bayer Dental) was introduced through a small incision into the common carotid artery and advanced to a position 9 mm distal from a carotid bifurcation for occlusion of the MCA. A selective ARB, valsartan (provided by Novartis Pharma AG),²⁵ was administered via an osmotic minipump (model 1002, Alza) implanted intraperitoneally 10 days before MCA occlusion.

Brain samples were obtained 24 hours after MCA occlusion, and coronal sections of 1-mm thickness were immediately stained with 2% 2,3,5-triphenyltetrazolium chloride (TTC) as previously described.^24,26 Neurological deficit was evaluated 24 hours after MCA occlusion by use of neurological scores developed by Huang et al.²⁷ Blood pressure was measured by the indirect tail-cuff method with a blood pressure monitor (MK-1030, Muromachi Kikai Co Ltd).

Laser-Doppler Flowmetry
Cerebral blood flow was determined in the territory of the MCA by laser-Doppler flowmetry using a flexible fiberoptic extension to the master probe (Omegaflo FLO-C1, Omegawave). The tip of the probe was fixed to the intact skull over the supplying territory of the proximal part of the MCA (core; 2 mm caudal to bregma and 6 mm lateral to midline)^28,29 and the peripheral part of the MCA (periphery; 2 mm caudal to bregma and 3 mm lateral to midline)²⁹ by use of a tissue adhesive (Aron Alpha; Toa). Changes in cerebral blood flow after MCA occlusion were expressed as percentage of the baseline value of laser-Doppler flowmetry.

Detection of Superoxide Anion in Brain Sections
Histological detection of superoxide anion was performed as described previously.³⁰ In brief, frozen, enzymatically intact, 10-µm-thick sections were prepared from mouse brain 24 hours after MCA occlusion and incubated immediately with dihydroethidium (DHE; 10 µmol/L) in PBS for 30 minutes at 37°C in a humidified chamber protected from light. DHE is oxidized on reaction with superoxide to ethidium, which binds to DNA in the nucleus and fluoresces red. For detection of ethidium, samples were examined with an Axioskop microscope (Axioskop 2 plus with AxioCam, Carl Zeiss) equipped with a computer-based imaging system. The intensity of the fluorescence was analyzed and quantified by use of computer-imaging software (Densitograph, ATTO Corp).

NADPH Oxidase Activity
The activity of NADPH oxidase in brain was measured according to the method of Pagano et al.³¹ Briefly, contralateral and ipsilateral cortices of the brain were obtained 24 hours after MCA occlusion. They were homogenized in 10 volumes of ice-cold Tris-sucrose buffer, and the enzyme activity was determined by use of the cytochrome c assay with or without superoxide dismutase.³¹

Statistical Analysis
Values are expressed as mean±SEM in the text and figures. The data were analyzed by 2-way ANOVA. If a statistically significant effect was found, post hoc analysis was performed to detect the difference between the groups. A value of P<0.05 was considered to be statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Focal Ischemic Injury of Brain After MCA Occlusion in Agtr2^– Mice
Focal brain ischemia was induced by MCA occlusion with the intraluminal filament technique. In Agtr2⁺ mice, the maximal ischemic area was 25% of the total area around section 3, which is in the territory of the MCA (Figure 1). The ischemic area of the brain was significantly larger in Agtr2^– mice. Neurological score at 24 hours after MCA occlusion was higher in Agtr2^– mice than in Agtr2⁺ mice (Figure 2). Systolic blood pressure 24 hours after MCA occlusion was not significantly different between Agtr2⁺ and Agtr2^– mice (Table).

View larger version (61K): [in this window] [in a new window]   Figure 1. Focal ischemic area of mouse brain 24 hours after MCA occlusion in angiotensin II type 2 (AT2) receptor–deficient mice. MCA occlusion was performed, and mouse brain was taken 24 hours later; coronal sections were stained with TTC as described in Methods. Brain sections are numbered from frontal (section 1) to caudal (section 6). Some mice were treated with valsartan (3 mg · kg–1 · d–1) for 10 days via an osmotic minipump before MCA occlusion, as described in Methods. a, TTC staining of brain sections from Agtr2+ mouse 24 hours after MCA occlusion. b, TTC staining of brain sections from Agtr2– mouse 24 hours after MCA occlusion. c, Morphometry of ischemic area determined with TTC staining and expressed as a percentage of total area. Agtr2+, wild-type; Agtr2–, AT2 receptor–deficient. n=7 to 8 for each group. *P<0.05 vs Agtr2+. Values are mean±SEM.

View larger version (12K): [in this window] [in a new window]   Figure 2. Neurological score of AT2 receptor–deficient mice after MCA occlusion. MCA occlusion was performed, and neurological score was used to evaluate neurological deficit 24 hours after operation, as described in Methods. Some mice were treated with valsartan (3 mg · kg–1 · d–1) for 10 days via an osmotic minipump before MCA occlusion as described in Methods. Agtr2+, wild-type; Agtr2–, AT2 receptor–deficient. n=7 to 8 for each group. *P<0.05 vs Agtr2+. Values are mean±SEM.

View this table: [in this window] [in a new window]   Blood Pressure Change After MCA Occlusion in WT and AT2KO Mice

Changes in Cerebral Blood Flow After MCA Occlusion in Agtr2^– Mice
Cerebral surface blood flow was measured in the core region and peripheral region of the MCA territory (Figure 3). Cerebral blood flow decreased just after MCA occlusion to 10% of the basal level in the core region and to 60% in the periphery in Agtr2⁺ mice (Figure 3). This reduction of cerebral blood flow continued for at least 24 hours after MCA occlusion in Agtr2⁺ mice. The decrease in cerebral blood flow in the core was not significantly different between Agtr2^– and Agtr2⁺ mice (Figure 3). However, cerebral blood flow in the peripheral region was significantly attenuated in Agtr2^– mice (Figure 3).

View larger version (23K): [in this window] [in a new window]   Figure 3. Change in cerebral blood flow after MCA occlusion in AT2 receptor–deficient mice. Surface cerebral blood flow was determined immediately and at 1 hour and 24 hours after MCA occlusion by laser-Doppler flowmetry as described in Methods. Blood flow change was expressed as a percentage of basal flow rate. Some mice were treated with valsartan (3 mg · kg–1 · d–1) for 10 days via an osmotic minipump before MCA occlusion as described in Methods. Agtr2+, wild-type; Agtr2–, AT2 receptor–deficient. n=6 to 8 for each group. *P<0.05 vs Agtr2+. P<0.05 vs without valsartan. Values are mean±SEM.

Oxidative Stress in Mouse Brain After MCA Occlusion
To assess the involvement of oxidative stress in the exaggeration of focal brain ischemia, superoxide anion production was evaluated (Figure 4). Superoxide anion production was increased in the occluded side but not in the nonoccluded side. Superoxide production in the ischemic area was enhanced in Agtr2^– mice. Moreover, the activity of NADPH oxidase was measured in brain cortices 24 hours after MCA occlusion (Figure 5). NADPH oxidase activity was increased after MCA occlusion. This increase was enhanced in AT₂KO mice (Figure 5).

View larger version (47K): [in this window] [in a new window]   Figure 4. Detection of superoxide anion production in mouse brain 24 hours after MCA occlusion. Freshly frozen sections of brain were prepared and superoxide anion production was detected with DHE (10 µmol/L) as described in Methods. Some mice were treated with valsartan (3 mg · kg–1 · d–1) for 10 days via an osmotic minipump before MCA occlusion as described in Methods. a, Photos are reproducible staining of brain sections (cortex) from nonischemic and ischemic areas. b, Intensity analysis of superoxide production stained with DHE. Intensity of fluorescence was determined by use of computer-imaging software as described in Methods. Agtr2+, wild-type; Agtr2–, AT2 receptor–deficient. n=6 to 8 for each group. *P<0.05 vs nonischemic area. P<0.01 vs without valsartan. P<0.05 vs Agtr2+ without valsartan. P<0.05 vs without valsartan. Values are mean±SEM.

View larger version (18K): [in this window] [in a new window]   Figure 5. NADPH oxidase activity in brain cortices 24 hours after MCA occlusion. Protein samples were prepared from brain cortices, and enzyme activity was assayed as described in Methods. Some mice were treated with valsartan (3 mg · kg–1 · d–1) for 10 days via an osmotic minipump before MCA occlusion. Agtr2+, wild-type; Agtr2–, AT2 receptor-deficient. n=6 to 7 for each group. *P<0.05 vs nonischemic area. P<0.05 vs without valsartan. P<0.05 vs Agtr2+ without valsartan. Values are mean±SEM.

Effect of ARB on Focal Brain Ischemia After MCA Occlusion
Administration of an ARB, valsartan, at a dose of 3 mg · kg^–1 · d^–1 for 10 days before MCA occlusion significantly suppressed mortality, neurological score, and the ischemic area of the brain in Agtr2⁺ mice (Figures 1 and 2 ), with no apparent change in blood pressure (Table). Valsartan also inhibited the reduction of cerebral blood flow in the peripheral region (Figure 3) and the increase in superoxide anion production as well as NADPH oxidase activity in the infarcted side of the brain after MCA occlusion in Agtr2⁺ mice (Figures 4 and 5). These effects of valsartan were significantly weaker in Agtr2^– mice than in Agtr2⁺ mice (Figures 1 to 5).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the present study, focal cerebral ischemia was induced by a silicon-coated microfilament guided into the MCA. The present study showed that the focal ischemic area induced by MCA occlusion was exaggerated in Agtr2^– mice. These results suggest that the AT₂ receptor plays an important role in cerebral ischemia, showing an antagonistic action against AT₁ receptor–mediated effects. Moreover, it was suggested that such antagonism of AT₂ receptor–mediated actions are involved in the effects of ARB, because the inhibitory effect of valsartan on the ischemic area was significantly weaker in Agtr2^– mice. The antagonistic action of AT₂ receptor stimulation seems to be mediated, at least in part, by modulation of cerebral blood flow and oxidative stress in the ischemic region.

As reported previously, the ischemic region can be separated into the infarct core, in which oxygen supply is too low to sustain cell viability, and the ischemic penumbra.²⁴ The penumbra is considered to be a border zone between the region in which electrical activity of neurons ceases and that exhibiting membrane depolarization. In the present study, we measured surface cerebral blood flow in the core and peripheral regions of the MCA territory. The decrease in cerebral blood flow in the peripheral region (penumbra) was exaggerated in Agtr2^– mice, and the inhibitory effect of valsartan on blood flow reduction was smaller in Agtr2^– mice than in Agtr2⁺ mice (Figure 3). These results indicate that the AT₁ and AT₂ receptors are involved in cerebral blood flow distribution. The reduction in the focal ischemic area in valsartan-treated mice may be caused by inhibition of blood flow reduction in the peripheral region (Figure 3). Therefore, blockade of the AT₁ receptor and stimulation of the AT₂ receptor show a protective effect on ischemic brain lesions. In receptor gene–deficient mice, it seems possible that the change of microcirculation, including collaterals, may have already developed under basal conditions before MCA occlusion, because the reduction of cerebral blood flow immediately after MCA occlusion in the peripheral region tended to be exaggerated in Agtr2^– mice (Figure 3). Treatment of Agtr2⁺ mice with valsartan inhibited a reduction of surface cerebral blood flow in the periphery. This inhibitory action of valsartan on reduction of cerebral blood flow was also weaker in Agtr2^– mice (Figure 3). These results also indicate the importance of AT₁ receptor blockade to improve brain ischemia and the involvement of AT₂ receptor stimulation in the action of ARBs. A previous report indicated that AT₂ receptor stimulation promoted axonal regeneration in the optic nerve.³² These results, together with those in the present study, suggest the potential neural protective action of AT₂ receptor stimulation.

Oxidative stress is considered to be involved in various pathological processes. ^33–35 It has been reported that brain ischemia enhances oxidative stress.^35,36 As reported previously, Ang II increases NADPH oxidase activity and stimulates production of reactive oxygen species, including the superoxide anion, through AT₁ receptors.^37–39 However, the role of the AT₂ receptor in oxidative stress is not yet fully understood. The present study demonstrated an inhibitory effect of AT₂ receptor stimulation on superoxide production using a combination of gene-deficient mice and an ARB (Figure 4). MCA occlusion increased oxidative stress in the ischemic area (Figures 4 and 5). Production of superoxide anion and NADPH oxidase activity in the ischemic area was exaggerated in Agtr2^– mice, whereas valsartan attenuated both superoxide production and NADPH oxidase activity in Agtr2⁺ mice. Moreover, the inhibitory effect of valsartan was smaller in Agtr2^– mice. These results suggest that modulation of local superoxide production by AT₁- and AT₂-receptor stimulation is involved in the development of ischemic brain lesions. A previous article also indicated that stimulation of the AT₂ receptor decreased the expression of NADPH oxidase subunit.³⁹ Thus, the regulatory action of AT₁- and AT₂-receptor stimulation on superoxide production may appear, at least in part, through the synthesis and activity of the NADPH oxidase subunit. Further examinations are needed to clarify the signal transduction pathways in the AT₂ receptor–mediated response.

Because valsartan was administered intraperitoneally, it is possible that it may have affected the ischemic brain area through indirect actions on peripheral hemodynamics. However, this may not be the case in our study, because we used a nonhypotensive dose of valsartan, as described previously.^18,19 In addition, systolic blood pressure was not significantly different after MCA occlusion between Agtr2⁺ and Agtr2^– mice (Table). It is not yet clear how peripherally administered valsartan is effective in reducing the ischemic brain region. However, as reported previously, peripherally applied candesartan, an ARB, effectively inhibited the centrally mediated effects of Ang II.^40,41 Therefore, it seems probable that valsartan administered peripherally in the present study also was able to enter the ischemic brain lesion and block central AT₁ receptors.

Further investigations are necessary to examine the detailed expression pattern of AT₁ and AT₂ receptors in cerebral arteries and the possible direct action of AT₁- and AT₂-receptor stimulation on neural cells and glial cells.^42,43 It is also necessary to determine the detailed localization of oxidative stress in brain blood vessels, inflammatory cells, and neural tissues in the brain after ischemia; this should also be examined in future experiments.

	Acknowledgments

 
This work was supported by grants from the Ministry of Education, Science, Sports, and Culture of Japan; the Japan Research Foundation for Clinical Pharmacology; the Tokyo Biochemical Research Foundation; the Smoking Research Foundation; and the Mitsubishi Pharma Research Foundation.

	Footnotes

 
*The first 2 authors contributed equally to this work.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology, XXIII: the angiotensin II receptors. Pharmacol Rev. 2000; 52: 415–472.[Abstract/Free Full Text]

2. Jöhren O, Imboden H, Häuser W, et al. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res. 1997; 757: 218–227.[CrossRef][Medline] [Order article via Infotrieve]

3. Davisson RL, Oliverio MI, Coffman TM, et al. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000; 106: 103–106.[Medline] [Order article via Infotrieve]

4. Davisson RL, Yang G, Beltz TG, et al. The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res. 1998; 83: 1047–1058.[Abstract/Free Full Text]

5. Li Z, Iwai M, Wu L, et al. Role of AT₂ receptor in the brain in regulation of blood pressure and water intake. Am J Physiol. 2003; 284: H116–H121.

6. Dahlöf B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995–1003.[CrossRef][Medline] [Order article via Infotrieve]

7. Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875–886.[CrossRef][Medline] [Order article via Infotrieve]

8. Schiffrin EL. Progress in secondary prevention of stroke with PROGRESS. The Perindopril Protection Against Recurrent Stroke study. Curr Hypertens Rep. 2002; 4: 39–40.[Medline] [Order article via Infotrieve]

9. Maeda K, Hata R, Bader M, et al. Larger anastomoses in angiotensinogen-knockout mice attenuate early metabolic disturbances after middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1999; 19: 1092–1098.[CrossRef][Medline] [Order article via Infotrieve]

10. Walter T, Olah L, Christoph H, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J. 2002; 16: 169–176.[Abstract/Free Full Text]

11. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT₁ blockade normalizes cardiovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000; 31: 2478–2486.[Abstract/Free Full Text]

12. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999; 33: 613–621.[Abstract/Free Full Text]

13. Kaschina E, Unger T. Angiotensin AT₁/AT₂ receptors: regulation, signalling and function. Blood Press. 2003; 12: 70–88.[CrossRef][Medline] [Order article via Infotrieve]

14. Gallinat S, Busche S, Raizada MK, et al. The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol. 2000; 278: E357–E374.

15. Jöhren O, Imboden H, Häuser W, et al. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res. 1997; 757: 218–227.[CrossRef][Medline] [Order article via Infotrieve]

16. Häuser W, Jöhren O, Saavedra JM. Characterization and distribution of angiotensin II receptor subtypes in the mouse brain. Eur J Pharmacol. 1998; 348: 101–114.[CrossRef][Medline] [Order article via Infotrieve]

17. Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT₂ receptor expression and signaling. Physiol Genomics. 2000; 2: 13–20.[Abstract/Free Full Text]

18. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001; 104: 2716–2721.[Abstract/Free Full Text]

19. Wu L, Iwai M, Nakagami H, et al. Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol. 2002; 22: 49–54.[Abstract/Free Full Text]

20. Lucius R, Gallinat S, Rosenstiel P, et al. The angiotensin II type 2 (AT₂) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998; 188: 661–670.[Abstract/Free Full Text]

21. Saavedra JM. Emerging features of brain angiotensin receptors. Regul Pept. 1999; 85: 31–45.[CrossRef][Medline] [Order article via Infotrieve]

22. Wright JW, Reichert JR, Davis CJ, et al. Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev. 2002; 26: 529–552.[CrossRef][Medline] [Order article via Infotrieve]

23. Vervoort VS, Beachem MA, Edwards PS, et al. AGTR2 mutations in X-linked mental retardation. Science. 2002; 296: 2401–2403.[Abstract/Free Full Text]

24. Hata R, Mies G, Wiessner C, et al. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab. 1998; 18: 367–375.[CrossRef][Medline] [Order article via Infotrieve]

25. Criscione L, Bradley W, Buhlmayer P, et al. Valsartan: preclinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev. 1995; 13: 230–250.[CrossRef]

26. Bederson JB, Pitts LH, Germano SM, et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986; 17: 1304–1308.[Abstract/Free Full Text]

27. Huang Z, Huang PL, Panahian N, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994; 265: 1883–1885.[Abstract/Free Full Text]

28. Connolly ES Jr, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest. 1996; 97: 209–216.[Medline] [Order article via Infotrieve]

29. Tabrizi P, Wang L, Seeds N, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol. 1999; 19: 2801–2806.[Abstract/Free Full Text]

30. Szöcs K, Lassegue B, Sorescu D, et al. Upregulation of NOx-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002; 22: 21–27.[Abstract/Free Full Text]

31. Pagano PJ, Clark JK, Cifuentes-Pagano ME, et al. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A. 1997; 94: 14483–14488.[Abstract/Free Full Text]

32. Lucius R, Gallinat S, Rosenstiel P, et al. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998; 188: 661–670.[Abstract/Free Full Text]

33. Williams RS, Benjamin IJ. Protective responses in the ischemic myocardium. J Clin Invest. 2000; 106: 813–818.[Medline] [Order article via Infotrieve]

34. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest. 2003; 111: 163–169.[CrossRef][Medline] [Order article via Infotrieve]

35. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001; 21: 2–14.[CrossRef][Medline] [Order article via Infotrieve]

36. Lerouet D, Beray-Berthat V, Palmier B, et al. Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats. Brain Res. 2002; 958: 166–175.[CrossRef][Medline] [Order article via Infotrieve]

37. Friberg H, Wieloch T, Castilho RF. Mitochondrial oxidative stress after global brain ischemia in rats. Neurosci Lett. 2002; 334: 111–114.[CrossRef][Medline] [Order article via Infotrieve]

38. Privratsky JR, Wold LE, Sowers JR, et al. AT₁ blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT₁ receptor and NADPH oxidase. Hypertension. 2003; 42: 206–212.[Abstract/Free Full Text]

39. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol. 2003; 285: R117–R124.

40. Gohlke P, von Kugelgen S, Jurgensen T, et al. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J Hypertens. 2002; 20: 909–918.[CrossRef][Medline] [Order article via Infotrieve]

41. Culman J, Blume A, Gohlke P, et al. The renin-angiotensin system in the brain: possible therapeutic implications for AT₁-receptor blockers. J Hum Hypertens. 2002; 16: S64–S70.

42. Monti J, Schinke M, Bohm M, et al. Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Am J Physiol. 2001; 280: R233–R240.

43. Muscella A, Aloisi F, Marsigliante S, et al. Angiotensin II modulates the activity of Na⁺,K⁺-ATPase in cultured rat astrocytes via the AT₁ receptor and protein kinase C-delta activation. J Neurochem. 2000; 74: 1325–1331.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				S. Chen, G. Li, W. Zhang, J. Wang, C. D. Sigmund, J. E. Olson, and Y. Chen Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1526 - R1531. [Abstract] [Full Text] [PDF]

				N. Nacasch and Z. Korzets Worsening of hyperglycemia due to atorvastatin in a renal transplant patient NDT Plus, October 1, 2009; 2(5): 392 - 394. [Abstract] [Full Text] [PDF]

				A. P. Mecca, T. E. O'Connor, M. J. Katovich, and C. Sumners Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion Exp Physiol, August 1, 2009; 94(8): 937 - 946. [Abstract] [Full Text] [PDF]

				C. A. McCarthy, A. Vinh, J. K. Callaway, and R. E. Widdop Response to Letter by Tsuda Stroke, July 1, 2009; 40(7): e494 - e494. [Full Text] [PDF]

				A. Kozak, A. Ergul, A. B. El-Remessy, M. H. Johnson, L. S. Machado, H. F. Elewa, M. Abdelsaid, D. C. Wiley, and S. C. Fagan Candesartan Augments Ischemia-Induced Proangiogenic State and Results in Sustained Improvement After Stroke Stroke, May 1, 2009; 40(5): 1870 - 1876. [Abstract] [Full Text] [PDF]

				C. A. McCarthy, A. Vinh, J. K. Callaway, and R. E. Widdop Angiotensin AT2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke * Supplemental Materials and Methods Stroke, April 1, 2009; 40(4): 1482 - 1489. [Abstract] [Full Text] [PDF]

				S. Inaba, M. Iwai, Y. Tomono, I. Senba, M. Furuno, H. Kanno, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes Stroke, February 1, 2009; 40(2): 597 - 603. [Abstract] [Full Text] [PDF]

				S. Inaba, M. Iwai, M. Furuno, Y. Tomono, H. Kanno, I. Senba, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice Hypertension, February 1, 2009; 53(2): 356 - 362. [Abstract] [Full Text] [PDF]

				W. Kozak, A. Kozak, M. H. Johnson, H. F. Elewa, and S. C. Fagan Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 773 - 782. [Abstract] [Full Text] [PDF]

				J. Iwanami, M. Mogi, J.-M. Li, K. Tsukuda, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Deletion of Angiotensin II Type 2 Receptor Attenuates Protective Effects of Bone Marrow Stromal Cell Treatment on Ischemia-Reperfusion Brain Injury in Mice * Supplemental Materials and Methods Stroke, September 1, 2008; 39(9): 2554 - 2559. [Abstract] [Full Text] [PDF]

				N. Oyamada, M. Sone, K. Miyashita, K. Park, D. Taura, M. Inuzuka, T. Sonoyama, H. Tsujimoto, Y. Fukunaga, N. Tamura, et al. The Role of Mineralocorticoid Receptor Expression in Brain Remodeling after Cerebral Ischemia Endocrinology, August 1, 2008; 149(8): 3764 - 3777. [Abstract] [Full Text] [PDF]

				J.-M. Li, M. Mogi, J. Iwanami, L.-J. Min, K. Tsukuda, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density Stroke, July 1, 2008; 39(7): 2029 - 2036. [Abstract] [Full Text] [PDF]

				M. Shimamura, N. Sato, M. Sata, H. Kurinami, D. Takeuchi, K. Wakayama, T. Hayashi, H. Iida, and R. Morishita Delayed Postischemic Treatment With Fluvastatin Improved Cognitive Impairment After Stroke in Rats Stroke, December 1, 2007; 38(12): 3251 - 3258. [Abstract] [Full Text] [PDF]

				K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF]

				M. Yusof, K. Kamada, F. Spencer Gaskin, and R. J. Korthuis Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3032 - H3037. [Abstract] [Full Text] [PDF]

				N. Chitravas, H. M. Dewey, M. B. Nicol, D. L. Harding, D. C. Pearce, and A. G. Thrift Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology, May 15, 2007; 68(20): 1687 - 1693. [Abstract] [Full Text] [PDF]

				M. Mogi, J.-M. Li, J. Iwanami, L.-J. Min, K. Tsukuda, M. Iwai, and M. Horiuchi Angiotensin II Type-2 Receptor Stimulation Prevents Neural Damage by Transcriptional Activation of Methyl Methanesulfonate Sensitive 2 Hypertension, July 1, 2006; 48(1): 141 - 148. [Abstract] [Full Text] [PDF]

				N. Kobayashi, K. Yoshida, S. Nakano, T. Ohno, T. Honda, Y. Tsubokou, and H. Matsuoka Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts Hypertension, April 1, 2006; 47(4): 671 - 679. [Abstract] [Full Text] [PDF]

				M. Mogi, M. Iwai, and M. Horiuchi New Paradigm for Brain Protection After Stroke Hypertension, April 1, 2006; 47(4): 642 - 643. [Full Text] [PDF]

				A. Fournier, G. Choukroun, S. S. Modeliar, O. Godefroy, J.-M. Achard, J. Wang, and F. Messerli Does the MOSES Trial Establish Superiority of AT1-Receptor Blockers Over Dihydropyridine/Calcium Antagonists in Secondary Stroke Prevention? Stroke, February 1, 2006; 37(2): 336 - 337. [Full Text] [PDF]

				M. Iwai, R. Chen, Z. Li, T. Shiuchi, J. Suzuki, A. Ide, M. Tsuda, M. Okumura, L.-J. Min, M. Mogi, et al. Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein E-Null Mice Circulation, September 13, 2005; 112(11): 1636 - 1643. [Abstract] [Full Text] [PDF]

				M. Tsuda, M. Iwai, J.-M. Li, H.-S. Li, L.-J. Min, A. Ide, M. Okumura, J. Suzuki, M. Mogi, H. Suzuki, et al. Inhibitory Effects of AT1 Receptor Blocker, Olmesartan, and Estrogen on Atherosclerosis Via Anti-Oxidative Stress Hypertension, April 1, 2005; 45(4): 545 - 551. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. A. Barker, and B. C. Berk Angiotensin II and the Endothelium: Diverse Signals and Effects Hypertension, February 1, 2005; 45(2): 163 - 169. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/7/843    most recent 01.CIR.0000138848.58269.80v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwai, M. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Iwai, M. Articles by Horiuchi, M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors Animal models of human disease